In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses recent breakthroughs demonstrating that gene ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

Whether or not to cover these procedures, and if so, coverage details, should be decided on before their popularity grows.

Researchers at Washington University School of Medicine in St. Louis have described the neurodegeneration that occurs in the ...

Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the ...

Life-changing gene therapies for hemophilia have become available, yet many patients and providers have not yet rushed to try ...

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.

Spark Therapeutics is on the cusp of gaining the first ever approval for a gene therapy from the FDA ... about creative payment models? No thanks; can we talk about your haemophilia drug?” ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Joe DePinto, MBA, discussed the findings of the McKesson 2024 Cell and Gene Therapy Report, providing insight into the challenges and opportunities in equitable access to these treatments.

The discussion of bioprocess innovation has traditionally focused on high-throughput analytics, machine learning, and automation but less so on the systems that capture the data they generate, ...

A preview of Nebraska Medicine's Innovation Design Unit in December 2024 After more than four decades of infusing himself with the blood clotting factor his body can’t make, Chad Stevens decided ...